<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9681">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00730015</url>
  </required_header>
  <id_info>
    <org_study_id>MCP-103-303</org_study_id>
    <nct_id>NCT00730015</nct_id>
  </id_info>
  <brief_title>Trial of Linaclotide in Patients With Chronic Constipation</brief_title>
  <official_title>A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide Administered Orally for 12 Weeks Followed by a 4-Week Randomized Withdrawal Period in Patients With Chronic Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ironwood Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ironwood Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to determine the efficacy and safety of linaclotide
      administered to patients with chronic constipation (CC). The primary efficacy parameter is
      the percentage of patients in each dosing group that meet the protocol definition for
      Complete Spontaneous Bowel Movement (CSBM) Overall Responder.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Complete Spontaneous Bowel Movement (CSBM) Overall Responder</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>A 12-week CSBM Overall Responder was defined as a patient who for at least 9 of the 12 weeks of the treatment period had a CSBM weekly frequency rate that was 3 or greater and increased by 1 or more from baseline. A CSBM was defined as a spontaneous bowel movement (SBM) that was associated with a sense of complete evacuation.
An SBM was defined as a bowel movement (BM) that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>12-Week Complete Spontaneous Bowel Movement (CSBM) Frequency</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of CSBMs per week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Week Spontaneous Bowl Movement (SBM) Frequency</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of SBMs per week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-week Change in Stool Consistency</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The consistency of each BM was assessed using the 7-point Bristol Stool Form Scale:
= separate hard lumps like nuts [difficult to pass]
= sausage shaped but lumpy
= like a sausage but with cracks on surface
= like a sausage or snake, smooth and soft
= soft blobs with clear-cut edges [passed easily]
= fluffy pieces with ragged edges, a mushy stool
= watery, no solid pieces [entirely liquid]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-week Change in Severity of Straining</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Severity of Straining is measured on a 5-point scale, where a value of 1 is &quot;not at all&quot; and a value of 5 is &quot;an extreme amount&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-week Change in Abdominal Discomfort</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Abdominal discomfort is based on a 5-point scale where a value of l is &quot;none&quot; and a value of 5 is &quot;very severe.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-week Change in Bloating</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Bloating was based on a 5-point scale where a value of l is &quot;none&quot; and a value of 5 is &quot;very severe&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-week Change in Constipation Severity</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Constipation severity was based on a 5-point ordinal scale where a value of l is &quot;none&quot; and a value of 5 is &quot;very severe&quot;.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">643</enrollment>
  <condition>Chronic Constipation</condition>
  <arm_group>
    <arm_group_label>145 μg linaclotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>290 μg linaclotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Oral, once daily</description>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linaclotide</intervention_name>
    <description>Oral, once daily</description>
    <arm_group_label>145 μg linaclotide</arm_group_label>
    <arm_group_label>290 μg linaclotide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has completed a colonoscopy according to the AGA criteria, with no clinically
             significant findings

          -  Patient has successfully completed protocol procedures (with no clinically
             significant findings): physical exam, 12-lead ECG, or clinical laboratory tests

          -  Patient meets protocol criteria for CC: reports &lt; 3 bowel movements per week and
             reports straining, lumpy or hard stools, and/or sensation of incomplete evacuation
             during &gt; 25% of BMs

          -  Patient demonstrates continued chronic constipation through Pretreatment Period

          -  Patient is compliant with IVRS

        Exclusion Criteria:

          -  Patient has history of loose or watery stools

          -  Patient has symptoms of or been diagnosed with Irritable Bowel Syndrome (IBS)

          -  Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease
             or condition that can affect GI motility

          -  Patient has any protocol-excluded or clinically significant medical or surgical
             history that could confound the study assessments
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey M. Johnston, MD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>Ironwood Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Tuscon</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Sherwood</city>
        <state>Arkansas</state>
        <zip>72120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>San Carlos</city>
        <state>California</state>
        <zip>94070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Connecticut</state>
        <zip>06010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Clive</city>
        <state>Iowa</state>
        <zip>50325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <zip>52807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Mission</city>
        <state>Kansas</state>
        <zip>66202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Hollywood</city>
        <state>Maryland</state>
        <zip>20636</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Laurel</city>
        <state>Maryland</state>
        <zip>20707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Michigan</state>
        <zip>48047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Cedar Knolls</city>
        <state>New Jersey</state>
        <zip>07927</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Ocean</city>
        <state>New Jersey</state>
        <zip>07712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Pittsford</city>
        <state>New York</state>
        <zip>14534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Asheboro</city>
        <state>North Carolina</state>
        <zip>27203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Harrisburg</city>
        <state>North Carolina</state>
        <zip>28075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>North Carolina</state>
        <zip>28546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Summerville</city>
        <state>North Carolina</state>
        <zip>29485</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45440</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <zip>43560</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Wadsworth</city>
        <state>Ohio</state>
        <zip>44281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <zip>43701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Yukon</city>
        <state>Oklahoma</state>
        <zip>73099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>19606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Levittown</city>
        <state>Pennsylvania</state>
        <zip>19056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Sellersville</city>
        <state>Pennsylvania</state>
        <zip>18960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <zip>29681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>LaCrosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 19, 2012</lastchanged_date>
  <firstreceived_date>August 5, 2008</firstreceived_date>
  <firstreceived_results_date>September 28, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patient Recruitment occurred from August 2008 to August 2009 at 109 U.S. study centers.</recruitment_details>
      <pre_assignment_details>Patients went through a 14 to 21 day Pretreatment Period during which the patients provided qualifying bowel habit and symptoms, and rescue medicine usage information through an interactive voice response system (IVRS).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Linaclotide, 145μg</title>
          <description>Linaclotide, 145μg dose, oral administration, once per day</description>
        </group>
        <group group_id="P2">
          <title>Linaclotide, 290μg</title>
          <description>Linaclotide, 290μg dose, oral administration, once per day</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Dose matched placebo, oral administration, once per day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="217"/>
                <participants group_id="P2" count="217"/>
                <participants group_id="P3" count="209"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="186"/>
                <participants group_id="P2" count="177"/>
                <participants group_id="P3" count="177"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Linaclotide, 145μg</title>
          <description>Linaclotide, 145μg dose, oral administration, once per day</description>
        </group>
        <group group_id="B2">
          <title>Linaclotide, 290μg</title>
          <description>Linaclotide, 290μg dose, oral administration, once per day</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Dose matched placebo, oral administration, once per day</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="217"/>
                <measurement group_id="B2" value="217"/>
                <measurement group_id="B3" value="209"/>
                <measurement group_id="B4" value="643"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="47.1" spread="14.2"/>
                <measurement group_id="B2" value="47.7" spread="14.2"/>
                <measurement group_id="B3" value="49.3" spread="14.3"/>
                <measurement group_id="B4" value="48.0" spread="14.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>18 years to 64 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="190"/>
                <measurement group_id="B2" value="190"/>
                <measurement group_id="B3" value="181"/>
                <measurement group_id="B4" value="561"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>65 years and older</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
                <measurement group_id="B2" value="27"/>
                <measurement group_id="B3" value="28"/>
                <measurement group_id="B4" value="82"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="191"/>
                <measurement group_id="B2" value="189"/>
                <measurement group_id="B3" value="182"/>
                <measurement group_id="B4" value="562"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
                <measurement group_id="B2" value="28"/>
                <measurement group_id="B3" value="27"/>
                <measurement group_id="B4" value="81"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="217"/>
                <measurement group_id="B2" value="217"/>
                <measurement group_id="B3" value="209"/>
                <measurement group_id="B4" value="643"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Spontaneous Bowel Movement (CSBM) Overall Responder</title>
        <description>A 12-week CSBM Overall Responder was defined as a patient who for at least 9 of the 12 weeks of the treatment period had a CSBM weekly frequency rate that was 3 or greater and increased by 1 or more from baseline. A CSBM was defined as a spontaneous bowel movement (SBM) that was associated with a sense of complete evacuation.
An SBM was defined as a bowel movement (BM) that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.</description>
        <time_frame>Change from Baseline to Week 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>643 randomized patients received at least 1 dose of study drug. 642 patients were included in the Intent to Treat (ITT) Population. An observed-cases approach to missing postbaseline data was applied.</population>
        <group_list>
          <group group_id="O1">
            <title>Linaclotide, 145μg</title>
            <description>Linaclotide, 145μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O2">
            <title>Linaclotide, 290μg</title>
            <description>Linaclotide, 290μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Dose matched placebo, oral administration, once per day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="217"/>
                  <measurement group_id="O2" value="216"/>
                  <measurement group_id="O3" value="209"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Complete Spontaneous Bowel Movement (CSBM) Overall Responder</title>
            <description>A 12-week CSBM Overall Responder was defined as a patient who for at least 9 of the 12 weeks of the treatment period had a CSBM weekly frequency rate that was 3 or greater and increased by 1 or more from baseline. A CSBM was defined as a spontaneous bowel movement (SBM) that was associated with a sense of complete evacuation.
An SBM was defined as a bowel movement (BM) that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="42"/>
                  <measurement group_id="O3" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference in the proportion of 12-week CSBM overall responders between patients taking the 145-μg dose and those taking placebo. The power, adjusted for multiplicity, was expected to be at least 90% based on study NCT00402337(MCP-103-201) data.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value is still less than 0.05 after adjusting multiplicity using a serial gatekeeping multiple comparison procedure.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>7.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.41</ci_lower_limit>
            <ci_upper_limit>17.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference in the proportion of 12-week CSBM overall responders between patients taking the 290-μg dose and those taking placebo. The power, adjusted for multiplicity, was expected to be greater than 96% based on study NCT00402337(MCP-103-201) data.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value is still less than 0.05 after adjusting multiplicity using a serial gatekeeping multiple comparison procedure.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>7.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.14</ci_lower_limit>
            <ci_upper_limit>16.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12-Week Complete Spontaneous Bowel Movement (CSBM) Frequency</title>
        <description>The number of CSBMs per week.</description>
        <time_frame>Change from Baseline to Week 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>643 randomized patients received at least 1 dose of study drug. 642 patients were included in the ITT Population. An observed-cases approach to missing postbaseline data was applied.</population>
        <group_list>
          <group group_id="O1">
            <title>Linaclotide, 145μg</title>
            <description>Linaclotide, 145μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O2">
            <title>Linaclotide, 290μg</title>
            <description>Linaclotide, 290μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Dose matched placebo, oral administration, once per day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="217"/>
                  <measurement group_id="O2" value="216"/>
                  <measurement group_id="O3" value="209"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>12-Week Complete Spontaneous Bowel Movement (CSBM) Frequency</title>
            <description>The number of CSBMs per week.</description>
            <units>CSBMs per Week</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.94" spread="0.17"/>
                  <measurement group_id="O2" value="2.04" spread="0.17"/>
                  <measurement group_id="O3" value="0.45" spread="0.17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12-Week Spontaneous Bowl Movement (SBM) Frequency</title>
        <description>The number of SBMs per week.</description>
        <time_frame>Change from Baseline to Week 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>643 randomized patients received at least 1 dose of study drug. 642 patients were included in the ITT Population. An observed-cases approach to missing postbaseline data was applied.</population>
        <group_list>
          <group group_id="O1">
            <title>Linaclotide, 145μg</title>
            <description>Linaclotide, 145μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O2">
            <title>Linaclotide, 290μg</title>
            <description>Linaclotide, 290μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Dose matched placebo, oral administration, once per day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="217"/>
                  <measurement group_id="O2" value="216"/>
                  <measurement group_id="O3" value="209"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>12-Week Spontaneous Bowl Movement (SBM) Frequency</title>
            <description>The number of SBMs per week.</description>
            <units>SBMs per Week</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3.03" spread="0.21"/>
                  <measurement group_id="O2" value="2.98" spread="0.21"/>
                  <measurement group_id="O3" value="1.08" spread="0.22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12-week Change in Stool Consistency</title>
        <description>The consistency of each BM was assessed using the 7-point Bristol Stool Form Scale:
= separate hard lumps like nuts [difficult to pass]
= sausage shaped but lumpy
= like a sausage but with cracks on surface
= like a sausage or snake, smooth and soft
= soft blobs with clear-cut edges [passed easily]
= fluffy pieces with ragged edges, a mushy stool
= watery, no solid pieces [entirely liquid]</description>
        <time_frame>Change from Baseline to Week 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>643 randomized patients received at least 1 dose of study drug; 642 patients were included in the ITT Population; 101 patients with no pretreatment spontaneous bowel movements were excluded from the Stool Consistency analysis. An observed-cases approach to missing postbaseline data was applied.</population>
        <group_list>
          <group group_id="O1">
            <title>Linaclotide, 145μg</title>
            <description>Linaclotide, 145μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O2">
            <title>Linaclotide, 290μg</title>
            <description>Linaclotide, 290μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Dose matched placebo, oral administration, once per day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="183"/>
                  <measurement group_id="O2" value="181"/>
                  <measurement group_id="O3" value="177"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>12-week Change in Stool Consistency</title>
            <description>The consistency of each BM was assessed using the 7-point Bristol Stool Form Scale:
= separate hard lumps like nuts [difficult to pass]
= sausage shaped but lumpy
= like a sausage but with cracks on surface
= like a sausage or snake, smooth and soft
= soft blobs with clear-cut edges [passed easily]
= fluffy pieces with ragged edges, a mushy stool
= watery, no solid pieces [entirely liquid]</description>
            <units>units on a scale</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.85" spread="0.08"/>
                  <measurement group_id="O2" value="1.84" spread="0.08"/>
                  <measurement group_id="O3" value="0.58" spread="0.09"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12-week Change in Severity of Straining</title>
        <description>Severity of Straining is measured on a 5-point scale, where a value of 1 is &quot;not at all&quot; and a value of 5 is &quot;an extreme amount&quot;.</description>
        <time_frame>Change from Baseline to Week 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>643 randomized patients received at least 1 dose of study drug; 642 patients were included in the ITT Population; 101 patients with no pretreatment spontaneous bowel movements were excluded from the Straining analysis. An observed-cases approach to missing postbaseline data was applied.</population>
        <group_list>
          <group group_id="O1">
            <title>Linaclotide, 145μg</title>
            <description>Linaclotide, 145μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O2">
            <title>Linaclotide, 290μg</title>
            <description>Linaclotide, 290μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Dose matched placebo, oral administration, once per day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="183"/>
                  <measurement group_id="O2" value="181"/>
                  <measurement group_id="O3" value="177"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>12-week Change in Severity of Straining</title>
            <description>Severity of Straining is measured on a 5-point scale, where a value of 1 is &quot;not at all&quot; and a value of 5 is &quot;an extreme amount&quot;.</description>
            <units>units on a scale</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.12" spread="0.05"/>
                  <measurement group_id="O2" value="-1.15" spread="0.05"/>
                  <measurement group_id="O3" value="-0.51" spread="0.05"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12-week Change in Abdominal Discomfort</title>
        <description>Abdominal discomfort is based on a 5-point scale where a value of l is &quot;none&quot; and a value of 5 is &quot;very severe.&quot;</description>
        <time_frame>Change from Baseline to Week 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>643 randomized patients received at least 1 dose of study drug. 642 patients were included in the ITT Population. An observed-cases approach to missing postbaseline data was applied.</population>
        <group_list>
          <group group_id="O1">
            <title>Linaclotide, 145μg</title>
            <description>Linaclotide, 145μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O2">
            <title>Linaclotide, 290μg</title>
            <description>Linaclotide, 290μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Dose matched placebo, oral administration, once per day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="217"/>
                  <measurement group_id="O2" value="216"/>
                  <measurement group_id="O3" value="209"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>12-week Change in Abdominal Discomfort</title>
            <description>Abdominal discomfort is based on a 5-point scale where a value of l is &quot;none&quot; and a value of 5 is &quot;very severe.&quot;</description>
            <units>units on a scale</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.49" spread="0.04"/>
                  <measurement group_id="O2" value="-0.44" spread="0.04"/>
                  <measurement group_id="O3" value="-0.30" spread="0.04"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12-week Change in Bloating</title>
        <description>Bloating was based on a 5-point scale where a value of l is &quot;none&quot; and a value of 5 is &quot;very severe&quot;.</description>
        <time_frame>Change from Baseline to Week 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>643 randomized patients received at least 1 dose of study drug. 642 patients were included in the ITT Population. An observed-cases approach to missing postbaseline data was applied.</population>
        <group_list>
          <group group_id="O1">
            <title>Linaclotide, 145μg</title>
            <description>Linaclotide, 145μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O2">
            <title>Linaclotide, 290μg</title>
            <description>Linaclotide, 290μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Dose matched placebo, oral administration, once per day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="217"/>
                  <measurement group_id="O2" value="216"/>
                  <measurement group_id="O3" value="209"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>12-week Change in Bloating</title>
            <description>Bloating was based on a 5-point scale where a value of l is &quot;none&quot; and a value of 5 is &quot;very severe&quot;.</description>
            <units>units on a scale</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.46" spread="0.04"/>
                  <measurement group_id="O2" value="-0.37" spread="0.04"/>
                  <measurement group_id="O3" value="-0.22" spread="0.04"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12-week Change in Constipation Severity</title>
        <description>Constipation severity was based on a 5-point ordinal scale where a value of l is &quot;none&quot; and a value of 5 is &quot;very severe&quot;.</description>
        <time_frame>Change from Baseline to Week 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>643 randomized patients received at least 1 dose of study drug; 642 patients were included in the ITT Population; 10 patients who dropped out prior to finishing 1 week of the trial have missing data. An observed-cases approach to missing postbaseline data was applied.</population>
        <group_list>
          <group group_id="O1">
            <title>Linaclotide, 145μg</title>
            <description>Linaclotide, 145μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O2">
            <title>Linaclotide, 290μg</title>
            <description>Linaclotide, 290μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Dose matched placebo, oral administration, once per day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="213"/>
                  <measurement group_id="O2" value="210"/>
                  <measurement group_id="O3" value="209"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>12-week Change in Constipation Severity</title>
            <description>Constipation severity was based on a 5-point ordinal scale where a value of l is &quot;none&quot; and a value of 5 is &quot;very severe&quot;.</description>
            <units>units on a scale</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.90" spread="0.05"/>
                  <measurement group_id="O2" value="-0.81" spread="0.05"/>
                  <measurement group_id="O3" value="-0.27" spread="0.05"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event data were collected from October 2008 through October 2009. The Treatment Period lasted 12 weeks and the Randomized Withdrawal (RW) Period started after the Treamtent Period and lasted 4 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Linaclotide 145μg</title>
          <description>Linaclotide, 145μg dose, oral administration, once per day</description>
        </group>
        <group group_id="E2">
          <title>Linaclotide 290μg</title>
          <description>Linaclotide, 290μg dose, oral administration, once per day</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Dose matched placebo, oral administration, once per day</description>
        </group>
        <group group_id="E4">
          <title>Placebo to Linaclotide 290μg Randomized Withdrawal (RW) Period</title>
          <description>Dose-matched placebo, oral administration, once per day or Linaclotide 290μg, oral administration, once per day.</description>
        </group>
        <group group_id="E5">
          <title>Linaclotide 145μg to Placebo RW Period</title>
          <description>Linaclotide 145μg, oral administration, once per day to Dose-matched placebo, oral administration, once per day</description>
        </group>
        <group group_id="E6">
          <title>Linaclotide 145μg to Linaclotide 145μg RW Period</title>
          <description>Linaclotide 145μg, oral administration, once per day to Linaclotide 145μg, oral administration, once per day</description>
        </group>
        <group group_id="E7">
          <title>Linaclotide 290μg to Placebo RW Period</title>
          <description>Linaclotide 290μg, oral administration, once per day to Dose-matched placebo, oral administration, once per day</description>
        </group>
        <group group_id="E8">
          <title>Linaclotide 290μg to Linaclotide 290μg RW Period</title>
          <description>Linaclotide 290μg, oral administration, once per day to Linaclotide 290μg, oral administration, once per day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulum intestinal hemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Parathyroid tumor benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="177"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="177"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The disclosure restriction on the PI is that publication cannot be made for 24 months from the date of final data lock of the study, the sponsor can review the publication prior to public release, sponsor requires a minimum 60 day review period for each publication, sponsor can request removal of confidential information of sponsor (not including results of trial), and sponsor can request an additional delay period of 60 days in order to protect potentially patentable information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Doug Levine, MD</name_or_title>
      <organization>Ironwood Pharmaceuticals</organization>
      <phone>617.374.3906</phone>
      <email>dlevine@ironwoodpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
